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ABSTRACT
OBJECTIVE: The study aims to characterize and discuss the processes of patient and public 
involvement (PPI) in the Brazilian Health Regulatory Agency (Anvisa), the National Committee 
for Health Technology Incorporation (Conitec), and the National Agency for Supplementary 
Health (ANS) in Brazil. 
METHODS: This is an exploratory, descriptive, and comparative study, conducted by analyzing 
the public documents and regulation of the three institutions.
RESULTS: The mechanisms for PPI included public consultations, public hearings, participation 
in advisory committees, and health technology evaluation requests. Anvisa conducted 187 public 
consultations between 1999 and 2018, gathering 10,699 contributions. In total, 76 (41%) public 
consultations did not present information about the contributions received. Conitec carried 
out 234 public consultations and received 53,174 contributions between 2011 and 2018. It was 
identified that 70 (23%) recommendations from Conitec did not go through public consultation, 
and 26 (8%) recommendations changed after public consultation. Recommendation changes 
seemed to have occurred especially in cases with a greater number of contributions in the 
public consultation process. ANS conducted eight public consultations regarding the list of 
health procedures and events covered by health insurances between 2000 and 2018, and it 
received 31,498 contributions. For three public consultations, there was no information about 
the number of contributions received.
CONCLUSIONS: There are regulatory advances and institutional activity supporting PPI in highly 
technical decision-making processes in Brazil, although heterogeneously among the analyzed 
institutions. The power of PPI to influence health technology deliberative processes still requires 
in-depth studies, including the characterization of stakeholders and the legitimacy of decisions.
DESCRIPTORS: Community Participation. Social Participation. Stakeholder Participation. 
Technology Assessment, Biomedical. Biomedical Technology. Brazilian Health Surveillance 
Agency. Supplemental Health.
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INTRODUCTION
The institutionality of patient and public involvement (PPI) – as well as the very construction of 
democracy – is associated with specific historical contexts1,2. Especially in Latin America, where 
political instability and structural inequalities are persistent, it has been challenging to propose 
and to maintain policies that ensure the participation of society in decision making processes1,2.
Community participation in health-related decisions has been included as a constitutional 
rule since the Brazilian Unified Health System (SUS) was created and has been regulated 
through as National Health Conferences and Health Councils3–5. In the following years, 
PPI was a subject of debate and political action, and other mechanisms for engagement in 
health decision-making were structured 6.
At the same time, the Política Nacional de Gestão de Tecnologias em Saúde (PNGTS—
National Policy on Health Technologies Management), established the use of technical and 
scientific knowledge in health decisions, even though it was based on the principle of public 
engagement7. In this document, the management of health technologies is defined as the 
processes of evaluation, incorporation, dissemination, use, and exclusion of technologies 
in the health system7. Therefore, it comprises regulatory approval of medicines, health 
care products, and other procedures related to health, as well as the decisions related to 
health insurance plans and incorporation of technologies in SUS. At the national level, 
the management of health technologies is carried out by the Brazilian Health Regulatory 
Agency (Anvisa), the National Committee for Health Technology Incorporation (Conitec) 
and the National Agency of Supplementary Health (ANS).
Anvisa’s activities include the regulatory approval of health technologies, from clinical 
trials to marketing authorization, with scientific proof of safety and efficacy8. Additional 
analyses on safety, efficacy, accuracy, and effectiveness, as well as comparative economic 
evaluation of benefits and costs with technologies already in the market are required in 
order to authorize the production and commercialization of a technology before its offer at 
SUS or its inclusion in the minimum list of supplemental health procedures and events4,9. 
The decision to incorporate, to exclude or to change technologies in SUS is the responsibility 
of the Brazilian Ministry of Health (MH), advised by Conitec4. In supplementary health, 
ANS Board of Directors is responsible for the aforementioned decision, after consulting the 
Comitê Permanente de Regulação da Atenção à Saúde (COSAÚDE—Permanent Healthcare 
Regulation Committee)9.
The institutions responsible for the management of health technologies must reconcile 
technical decisions and the social participation, following the Guidelines of SUS and the 
current regulation. Initiatives of PPI carried out by Anvisa, Conitec, and ANS were the subject 
of individual analyses in other studies10–14, but not yet comparatively based on the scope of 
health technology management, as described in PNGTS. This work aims to characterize and 
to discuss the mechanisms of patient and public involvement in the institutions responsible 
for the management of health technologies at the national level in Brazil.
METHODS
This is an exploratory, descriptive, and comparative study of the formal processes of patient and 
public involvement planned and implemented by Anvisa, Conitec, and ANS. For this purpose, 
documentary analysis was conducted as a method of data collection, consulting official 
documents and specific regulation. The primary source of information was the websites of the 
institutions, understood as the main tool for information access available to society. 
Documents published in the period between the legal creation of the institution and December 
2018 were included. Thus, for Anvisa, the period considered was between 1999 and 2018; 
between 2000 and 2018 for ANS; and for Conitec, between 2011 and 2018. Incomplete or 
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absent information was formally requested from the institutions with the channels provided 
for the Brazilian freedom of information law (Law No. 12,527/2011)15.
Descriptive analysis was used for data analysis. Information about the mechanisms of PPI 
formally planned and public consultations already carried out regarding health technologies 
were detailed for each institution. The presentation of public consultation was favored—
among other spaces—by the configuration of open participation, with direct communication 
between individuals and institutions, without the need for representatives16. Moreover, its 
realization is always prior to decision-making, with the prerogative of being able to amend it.
According to PNGTS, “medicines, equipment and technical procedures, organizational, 
informational, educational and support systems, and care programs and guidelines through 
which health care are provided to the population” are considered as health technologies7.
The mechanisms of PPI were identified as processes used by the society to express its 
demands. All individuals or legal entities that are not part of the governmental structure 
were considered as society, including those who access SUS and health insurance plans, 
institutions and health professionals, industry, and service sectors, as well as civil society 
organizations.
The processes of PPI were classified into five categories: health technology evaluation 
requests, participation in advisory committees, public consultations, public hearings, and 
ombudsman’s offices. Acting health technology evaluation requests is the society’s prerogative 
to initiate the process related to the management of technologies. It refers to the application 
for registration in Anvisa, incorporation in the SUS through Conitec or inclusion in ANS list.
Advisory committees refers to the participation of social representatives in collective 
instances, created by the public authorities’ initiative, like Health Councils. Consultations 
and public hearings are mechanisms in which any stakeholder can contribute, both in 
writing or in person. Institutional public ombudsman’s offices are instances of receipt, 
referral, and resolution of complaints, requests, and information related to public policies 
and services, which are open to any citizen16.
Public consultations carried out by each institution were categorized by theme and detailed 
regarding the deadline for sending contributions and number of contributions received. 
Public consultations carried out by areas of Anvisa related to medicines, health products, 
and food were included, because they fit the concept of health technology presented in 
PNGTS. Public consultations on pesticides, cosmetics, general sanitizer, tobacco, blood, 
tissues and organs, and internal management were excluded, because they dealt with topics 
other than technologies used in the direct provision of health care. Regarding inclusion, the 
deadline for submitting contributions should be until December 31, 2018.
For Conitec, public consultations on medicines, products or procedures were included, with 
processes closed until 2018. The date of publication of the decision by the MH was considered 
as the end of the process. The information about the contributions was obtained with the 
final version of the technical reports available on Conitec’s website. Public consultations 
on Protocolos Clínicos e Diretrizes Terapêuticas (CPTG—Clinical Protocols and Therapeutic 
Guidelines) were excluded, since they refer to documents guiding clinical conduct, services 
organization and implementation of technologies incorporated in previous decisions. 
The process of developing CPTG—including the mechanisms of PPI—deserves a thorough 
analysis14,17.
For ANS, it were included public consultations on the update of procedures and events 
covered by health insurances, therefore directly related to health technologies, held until 
2018. Public consultations on topics unrelated to the management of health technologies 
were excluded, such as the financial management issues of health insurance plan or 
document standardization.
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This work composes the research project “Social participation in the incorporation of 
technologies into SUS,” approved by the Research Ethics Committee of the Medical School 
of the Universidade de São Paulo. The documents used in this study are publicly accessible.
RESULTS
In total, 606 documents on the legal framework of the institutions and documents of 
processes conducted by them were analyzed. Out of these, the following were included: 187 
publications about public consultation and 99 social participation analysis reports made 
available by Anvisa; 304 technical reports published by Conitec; eight opening terms of 
public consultations and five public consultations reports published by ANS; in addition 
to the laws of creation of each institution (n = 3). The formal mechanisms of PPI identified 
in the institutions will be presented in a comparative way, followed by the details of the 
public consultations held.
Formal mechanisms of Patient and Public Involvement
The Box presents the formal mechanisms of PPI by institution. Only the producer of a certain 
technology can request from Anvisa the authorization to conduct clinical research, to 
produce, and to market new products. It is also up to them to demand the price specification 
of medicines and post-registration changes. Anvisa decisions on these issues are exclusively 
based on technical and procedural aspects, without formal opening to external participation, 
in addition to the plaintiff itself.
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Federal Council of Medicine; BCI: Brazilian Confederation of Industry; BTC: Brazilian Trade Confederation.
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The participation in advisory committees stems from Anvisa’s permanent advisory board and 
in temporary thematic sectoral chambers, both of advisory nature. Out of the 13 members 
of the permanent advisory board, eight are representatives of institutions interested in the 
agency’s regulation, and the others are federal, state, and municipal managers. It is expected 
that Anvisa conduct consultations and public hearings, but without mandatory aspect. 
Anvisa also has its own ombudsman’s office with legally defined competencies.
According to the regulation, any interested party may act as a plaintiff with Conitec and 
ANS aiming to the incorporation of their interests into the SUS or in supplemental health. 
The restrictions are technical and procedural in nature. Among the requirements, the 
systematized presentation of scientific evidence on clinical aspects of the technology and 
specific studies of economic evaluation and budgetary impact are highlighted.
Conitec’s recommendations regarding the request for incorporation are provided by a 
plenary, a permanent and deliberative committee. The deliberative character of the plenary 
refers to the possibility of vote of its members in relation to the final recommendation of 
the request for incorporation, even though the final decision relies on the MH. Among 
the 13 members of the plenary, there are representatives of the Brazilian Health Council 
(BHC) and Brazilian Federal Council of Medicine (BFCM). The other are from the MH itself 
(including all Departments, Anvisa, and ANS) and state and municipal managers.
Public consultations on the incorporation of technologies in the SUS are mandatory. 
The received contributions must be examined by the plenary before issuing the final 
recommendation. Public hearings are expected to be called in cases where they are 
considered relevant. Conitec does not have its own ombudsman’s office, but it is submitted 
to the general ombudsman’s office of the Brazilian Ministry of Health, therefore, Conitec 
is subject to mandatory reply.
The proposals for inclusion in the ANS list are discussed in the COSAÚDE, a permanent 
and advisory committee. Members include representatives of consumers, operators, health 
professionals, organized civil society with an interest in the sector, and government entities. 
consultations and public hearings are optional; in case of drafting of law in the agency’s 
scope the public hearings are exclusively mandatory. The ANS ombudsman’s office is specific 
and integrates its own organizational structure.
Public Consultations
Figure 1 shows the temporal comparison between the number of public consultations 
carried out by Anvisa, Conitec, and ANS about health technologies until 2018. 
Anvisa has carried out public consultations on health technologies since 2008, with an 
average and median of 17 public consultations per year and a total of 187 public consultations 
conducted between 2008 and 2018.
Conitec conducted an average of 33 public consultations per year between 2011 and 2018 
(median = 32), with a total of 234 public consultations in the period. It was observed that 70 
Conitec recommendations were issued without public consultation, despite its mandatory 
character, representing 23% of all recommendations between 2012 and 2018 (supplemental 
material). Out of these, 58 were recommendations for incorporation and 12 of exclusion 
(disinvestment), which came from the public sector. In total, 66 (94%) recommendations 
without public consultation were demanded by the Brazilian Ministry of Health itself. 
The others had as plaintiff Anvisa, Brazilian Council of Municipal Health Departments 
(CONASEMS), the Health Department of Pernambuco, and the Judiciary Branch.
ANS started the public consultations on the list of procedures and events in health in 
2004, with a biannual frequency, according to the periodicity expected to update the list. 
Eight public consultations were held between 2004 and 2018.
Figure 2 shows the comparison of contributions received in public consultations. 
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The volume of contributions received by Anvisa was at least 10,699. A total of 76 (41%) 
consultations did not have available information on their result, all dated before 2014. 
The number of contributions per consultation ranged between two and 3,531, with a 
contribution interval between 10 and 120 days.
Conitec received 53,174 contributions, an average of 227 contributions per public consultation 
(median = 4,245). The time for contributions ranged between 10 and 47 days. In 11 (5%) public 
consultations no suggestions were received. Contributions received in 2018 represent half 
of all contributions already received by Conitec.
ANS received 31,498 contributions in public consultations held on the update of the list 
between 2009 and 2018. No information was available on the volume of contributions 
Figure 1. Number of public consultations held per year, for each institution. Anvisa: Brazilian Health 
Regulatory Agency; Conitec: National Committee for Health Technology Incorporation; ANS: National 






















































Figure 2. Number of contributions received in public consultations per year, for each institution. Anvisa: 
Brazilian Health Regulatory Agency; Conitec: National Committee for Health Technology Incorporation 
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received in the three public consultations conducted before 2009. The average number of 
contributions received is 2,622 per public consultation (median = 6,338), and the deadline 
for sending contributions ranged between 12 and 60 days.
Regarding the themes, Anvisa carried out more public consultations about medicines 
(n = 81; 43%), followed by food (n = 60; 32%) and health care products (n = 46; 25%). Public 
consultations about food presented the highest volume of contributions (n = 6,274; 59%). 
Public consultations on medicines received 3,012 contributions (28%), and those on health 
care products received 1,413 (13%) contributions. 
For Conitec, public consultations about medicines were more frequent as well as they 
received more social inputs: 179 (76%) public consultations and 44,052 (83%) contributions. 
Procedures were the subject of 35 (15%) consultations and they had 1,870 (4%) contributions. 
Health care products were the subject of 20 (9%) consultations, with a total of 7,252 (14%) 
contributions received.
It was identified that 26 (8%) Conitec’s recommendations were changed after the public 
consultation, mainly from a negative preliminary recommendation to a final recommendation 
favorable to the incorporation. Most cases (73%) occurred in 2017 and 2018 and they had 
as plaintiff the company that produces the technology (62% of cases). Note that, out of the 
10 public consultations with the highest volume of contributions received by Conitec, four 
had the preliminary recommendation changed after the public consultation.
DISCUSSION
This study presented the mechanisms for patient and public involvement in Brazilian 
institutions responsible for the management of health technologies, at national level, as 
participation in advisory committees and direct participation of stakeholders by an initial 
demand or in public consultations, public hearings. Anvisa, Conitec, and ANS totaled 429 
public consultations and 95,371 contributions received in the period between the legal 
creation of the institution and December 2018, indicating the relevance related to public 
consultations as a mechanism of social participation in these institutions.
On the other hand, it was observed that means of social participation are heterogeneously 
in each institution. The differences observed in this study are related to the advisory or 
deliberative nature of the collective bodies, the qualification and quantity of representatives, 
the binding or discretion of holding public consultations and the provision of information 
on public consultations held and the effect on the final decisions.
Although included in a larger policy of health technologies management, it was observed 
that the three institutions have a different scope of action, with different objects of analysis 
and, consequently, different stakeholders and sources of political and social pressure. This  is 
reflected in the different conceptions of social participation observed among institutions.
The Health Technology Assessment (HTA)–the tool used in the three institutions to perform 
their evaluations–commonly uses the model of public involvement proposed by Gauvin et al.18. 
The model considers users of the health system, patients, and health professionals as interested 
in the HTA outcome. This model does not include, at least explicitly, key actors in health 
technologies management in Brazil: producers of technologies (such as the pharmaceutical 
industry), health insurance plan operators, and the judiciary branch.
In this study, it was observed that Conitec has a higher frequency of public consultations, due 
its mandate in health technology incorporation. However, it was identified that, approximately 
one in four Conitec recommendations, did not go through public consultation, especially 
when the health incorporation request was made by a governmental body.
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The distinct treatment provided by Conitec according to the origin of the demand was 
identified in previous studies19,20. Caetano and colleagues19 observed that 32% of Conitec’s 
recommendations on medicines by June 2016 were made without public consultation, including 
drugs without registration in Anvisa, all demanded by the MH. Yuba et al.20 observed that 
those demands from the public sector presented a higher frequency of recommendations 
favorable to incorporation, even though their reports did not present all formal requirements 
for clinical and economic evidence.
In this work on social participation, the public consultation also received differentiated 
treatment in government demands, the plaintiff’s proposal was approved without subjecting 
it to a public consultation, even if they were technologies of relevance to the population 
covered by SUS. Among the technologies not submitted to public consultations, there was 
an expressive volume of disinvestment, that is, the withdrawal of technologies that were 
offered by SUS. Among these cases, some technologies were highly sensitive, in which there 
is an important organization of civil society, such as people living with HIV and AIDS.
The changes in the recommendation about the incorporation of technologies into SUS 
after public consultations, especially in cases with a large volume of contributions, may 
indicate an institutional permeability to the intensity of patient and public involvement, if 
we consider that the large volume of contributions always implies greater interest of society, 
which requires, however, analysis of the segments that participated in the contributions. 
Silva et al.14 identified that six Conitec recommendations had the preliminary recommendation 
amended from “non-incorporation” to “incorporation” between 2012 and 2017. In five of them, 
a new price was proposed by the plaintiffs or relevant economic fact (availability of generic 
medicine) between the preliminary recommendation and the final recommendation14. 
These observations highlight the significance of economic and financial dimension in the 
decisions of technologies incorporation into SUS.
For Anvisa and ANS, the lack of mandatory public participation and the substantial 
information gap on the processes of social participation in its initial years of operation 
are highlighted, even after formal request. Other studies have also identified processes 
conducted by Anvisa10,12, Conitec14,21, and ANS13 aimed to involve society in their decisions. 
The absence of means of social participation and the advisory nature of the available 
mechanisms were indicated as significant limitations of an effective social participation 
in Anvisa and ANS10–13. Regarding Conitec, its recent implementation, lack of systematic 
and objective methods for analyzing contributions and absence of impact evaluation of the 
implemented initiatives were highlighted14,21.
Mechanisms of social participation are present in countries whose health system and 
technology management are examples for Brazil22–30. Several methods are used, with the 
inclusion of representatives in councils and committees22,24,27,28. Public consultations were 
identified in England, Canada (Ontario), Australia, and Germany to receive comments on 
national clinical reports and guidelines26,29,30.
The limitation of this study is the fact that only a quantitative measurement of the social 
participation in the decision-making arena was carried out, and not an evaluation of the 
effectiveness of social participation promoted by these organizations. Thus, the evaluation 
of how managers include the social contributions in their decision-making processes, if 
they do so, based on the demands of which interested parties and whether they promote 
equitable social participation is a significant aspect to be observed.
Another significant limitation of this is study is the absence of participants’ identification 
in these participatory venues. Companies, professionals, consumers, social movements, 
and isolated individuals were equal for this work, based on the definition of society as any 
individual or legal entity not part of the governmental structure. As regulatory institutions 
in a sector with large market interests, it would be mandatory to distinguish holdings with 
collective interests from private sector-friendly holdings only. Therefore, by using the term 
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social participation, we do not distinguish the general popular participation from the 
participation of direct stakeholders.
In conclusion, Anvisa, Conitec, and ANS expanded, over the period analyzed, the provision 
of formal means of social participation. However, there is no clear policy or homogeneity of 
implementation and organization of patient and public involvement mechanisms among 
the institutions analyzed. We observed that the great number of participation occurs with 
public consultations, especially about medicines. Thus, the power of social participation to 
influence health technology decision making processes still needs thorough studies. In addition 
to identifying the stakeholders in these social participation structures, it is important to 
know who actually occupies them and whether this promotes more legitimate decisions.
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